1306763-24-5

Basic information

• Product Name: (1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile
• Synonyms: (1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile;1H-Indene-4-carbonitrile, 2,3-dihydro-1-hydroxy-, (1R)-
• CAS NO: 1306763-24-5
• Molecular Formula: C10H9NO
• Molecular Weight: 159.18456
• Mol File: 1306763-24-5.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile(1306763-24-5)
• EPA Substance Registry System: (1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile(1306763-24-5)

Safety Data

• Hazardous Substances Data: 1306763-24-5(Hazardous Substances Data)

Usage

Description

(1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile is a chemical compound with the molecular formula C10H9NO. It is a derivative of indene, a bicyclic aromatic hydrocarbon, and features a hydroxy group and a carbonitrile group. The (1R) designation signifies the stereochemistry of the molecule, with the hydroxy group positioned on the first carbon of the indene ring. This unique structure and the presence of functional groups make it a candidate for organic synthesis and pharmaceutical development.

Uses

Used in Pharmaceutical Development:
(1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile is used as a building block in the synthesis of pharmaceuticals due to its unique structure and functional groups. The hydroxy and carbonitrile groups can be utilized in various chemical reactions to create new compounds with potential medicinal properties.
Used in Organic Synthesis:
In the field of organic synthesis, (1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile serves as a reagent or intermediate in the preparation of complex organic molecules. Its functional groups can be selectively modified to produce a range of chemical products, making it a versatile component in organic chemistry.
Used in Research and Development:
(1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile is also used in research and development settings to study the effects of stereochemistry on chemical reactions and to explore new synthetic pathways. Its unique structure provides opportunities for scientists to investigate novel reactions and mechanisms, contributing to the advancement of organic chemistry and pharmaceutical science.

Upstream product

• 15115-60-3 4-bromo-2,3-dihydroinden-1-one 
• 60899-34-5 4-cyano-2,3-dihydro-1H-inden-1-one 
• 25724-79-2 5-cyano-1-indanone 

Downstream Products

• 1201447-01-9 4-(5-(4-isopropoxy-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ol 
• 1201447-03-1 4-(5-(4-ethoxy-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ol 
• 1201447-07-5 2-ethoxy-5-(3-(1-hydroxy-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 
• 1201447-09-7 2-(4-(5-(4-isopropoxy-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ylamino)ethanol 
• 1201447-11-1 2-(4-(5-(4-ethoxy-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ylamino)ethanol 
• 1201447-94-0 4-(5-(4-ethoxy-3-nitrophenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ol 
• 1093827-52-1 (±)-4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ol 
• 1201446-43-6 4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-one 
• 1094042-01-9 CYM-5442 
• 1201446-74-3 N₁-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-N₂,N₂-diethylethane-1,2-diamine 
• 1307230-43-8 4-(5-(3,4-diethoxybenzyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ol 
• 1306763-71-2 (S)-tert-butyl 4-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ylcarbamate 

Relevant articles and documents

Enantioselective Synthesis of Ozanimod, the Active Pharmaceutical Ingredient of a New Drug for Multiple Sclerosis

We report here a short enantioselective synthesis of Ozanimod, a potent modulator of the enzyme Sphingosine-1-phosphate receptor (S1PR), recently approved by FDA and EMA for the treatment of relapsing-remitting multiple sclerosis. Amongst different synthetic approaches explored, we achieved the best result introducing the stereogenic centre in the last step through imine asymmetric transfer hydrogenation (ATH) using Wills’ catalysts. Besides the reduced numbers of enantiomeric purity controls required, this process culminates in an exceptionally high enantioselective reductive amination obtained with commercially available tethered Ru catalysts. Starting from commercially available 4-cyano-indanone, enantiomerically pure Ozanimod was obtained in 5 steps in 62 % overall yield and 99 % ee.

Method for preparing (S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile

The invention discloses a method for preparing (S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile. The method comprises the following steps: 1, adding 4-cyano-1-indanone to tetrahydrofuran, adding (S)-2-methyl-CBS-oxazaborolidine, cooling the obtained solut

HETERCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE

Described herein are heterocyclic compounds, compositions, and methods for their use for treatment of disease.